Metronomic Therapy with Chlorambucil and Piroxicam in Spontaneous Canine Cancers
Date Issued
2014
Date
2014
Author(s)
Huang, Chun-Yi
Abstract
Metronomic chemotherapy, the low-dose, frequently administered chemotherapy has revealed an important impact on the stabilization of cancer disease. Metronomic chemotherapy has revealed recently as an alternative treatment protocol to slow down cancer progression by its known antiangiogenic effect and modulation of immune status without severe adverse effects. The aim of this study was to evaluate the treatment outcome, tolerability and safety of a combination low-dose chlorambucil at a dosage of 3-4 mg/m2 daily and standard-dose piroxicam at a dosage of 0.3mg/kg in spontaneous canine cancers. In addition, the effects of Treg percentages of peripheral blood had been test to determine the function of immune modulation. 21 dogs were enrolled in the study. The median progression-free interval and the median survival time were 140 days and 261 days. In macroscopic disease dogs, overall remission rate was 20% (two of 10). SD was noted in five of 10 dogs (50%). Microscopic disease, without metastasis at the presentation and low to intermediated clinical stage had a significant longer survival time. All the side effects mostly limited to the grade I-II gastrointestinal signs (anorexia, nausea/vomiting or diarrhea) without any hematological or urological toxicity. Only one dog (5%) had elevated creatinine level during treatment. The protocol was well tolerated without severe adverse effects. By series examination of Treg level, there were significant decreasing in mean percentage and absolute number of regulatory T cell of the 28 -day period for the response or stable dogs.
In this study, metronomic chlorambucil with piroxicam revealed an acceptable antitumor effect in many kind of canine cancer without severe adverse effect.
Subjects
鐘擺式化療
低劑量化療
調節型T細胞
SDGs
Type
thesis
File(s)![Thumbnail Image]()
Loading...
Name
ntu-103-R00643001-1.pdf
Size
23.32 KB
Format
Adobe PDF
Checksum
(MD5):9ad7e10f696fa30e0121af088e053ad4